The TRAIL apoptotic pathway in cancer onset, progression and therapy

Nature Reviews Cancer

Volumn 8, Issue 10, 2008, Pages 782-798

  Johnstone, Ricky W ^a   Frew, Ailsa J ^a   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; AMG 655; BMS 3455541; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; GEFITINIB; GELDANAMYCIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SORAFENIB; TANESPIMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; BLADDER CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIVISION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; COUGHING; DRUG TARGETING; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; THORAX CANCER; THROMBOCYTOPENIA; TRANSAMINITIS; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 52649109068     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2465     Document Type: Review

References (216)

1. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
4. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nature Rev. Cancer 5, 876-885 (2005).
5. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420-430 (2002).
6. Smyth, M. J. et al. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18, 1-6 (2003).
7. Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J. & Okumura, K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95, 777-783 (2004).
8. Pitti, R. M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690 (1996).
9. Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995). References 8 and 9 describe the initial identification and cloning of TRAIL.
10. Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S. & El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770-2775 (1999).
11. Schneider, P. et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 278, 5444-5454 (2003).
12. Falschlehner, C., Emmerich, C. H., Gerlach, B. & Walczak, H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39, 1462-1475 (2007). References 5 and 12 provide excellent reviews of the molecular and biological activities of the TRAIL pathway.
13. Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255-260 (1999).
14. Willis, S. N. & Adams, J. M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617-625 (2005).
15. Keogh, S. A., Walczak, H., Bouchier-Hayes, L. & Martin, S. J. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett. 471, 93-98 (2000).
16. Walczak, H., Bouchon, A., Stahl, H. & Krammer, P. H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 60, 3051-3057 (2000).
17. Belka, C. et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20, 2190-2196 (2001).
18. Hinz, S. et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19, 5477-5486 (2000).
19. Fulda, S., Meyer, E. & Debatin, K. M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283-2294 (2002).
20. Zhang, X. D., Borrow, J. M., Zhang, X. Y., Nguyen, T. & Hersey, P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22, 2869-2881 (2003).
21. Rudner, J. et al. Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 24, 130-140 (2005).
22. Morel, J., Audo, R., Hahne, M. & Combe, B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280, 15709-15718 (2005).
23. Baader, E. et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 65, 7888-7895 (2005).
24. Ehrhardt, H. et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 22, 3842-3852 (2003).
25. Wagner, K. W. et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Med. 13, 1070-1077 (2007). Landmark paper describing how O-glycosylation of TRAILRs determines the relative sensitivity of cells to TRAIL-mediated apoptosis.
26. Muppidi, J. R. & Siegel, R. M. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nature Immunol. 5, 182-189 (2004).
27. Legler, D. F., Micheau, O., Doucey, M. A., Tschopp, J. & Bron, C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18, 655-664 (2003). References 26 and 27 describe how apoptotic signaling through death receptors may be regulated by the recruitment of receptors in lipid rafts.
28. Song, J. H. et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 67, 6946-6955 (2007).
29. Secchiero, P. & Zauli, G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr. Opin. Hematol. 15, 42-48 (2008).
30. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93 (2005). This key work demonstrated for the first time a role for TRAIL in immunoregulation.
31. Weckmann, M. et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nature Med. 13, 1308-1315 (2007).
32. Cretney, E., Shanker, A., Yagita, H., Smyth, M. J. & Sayers, T. J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 84, 87-98 (2006).
33. Hilliard, B. et al. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166, 1314-1319 (2001).
34. Lamhamedi-Cherradi, S. E., Zheng, S., Tisch, R. M. & Chen, Y. H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52, 2274-2278 (2003).
35. Zheng, S. J., Wang, P., Tsabary, G. & Chen, Y. H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113, 58-64 (2004).
36. Hoffmann, O. et al. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 117, 2004-2013 (2007).
37. Finnberg, N., Klein-Szanto, A. J. & El-Deiry, W. S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111-123 (2008).
38. Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 7, 94-100 (2001). A landmark paper first describing natural host TRAIL as an extrinsic tumor suppressor.
39. Kayagaki, N. et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163, 1906-1913 (1999).
40. Smyth, M. J. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670 (2001).
41. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosisinducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002).
42. Kayagaki, N. et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460 (1999).
43. Schmaltz, C. et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Med. 8, 1433-1437 (2002).
44. Wuchter, C. et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity. Leukemia 15, 921-928 (2001).
45. Inukai, T. et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 20, 2119-2129 (2006).
46. Tateishi, K. et al. TRAIL-induced cell death cooperates with IFN-γ activation in the graft-versus-tumor effect against colon tumors. Int. J. Cancer 118, 2237-2246 (2006).
47. Cassatella, M. A. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils. J. Leukoc. Biol. 79, 1140-1149 (2006).
48. Simons, M. P., Nauseef, W. M. & Griffith, T. S. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol. Res. 39, 79-93 (2007).
49. Song, K., Benhaga, N., Anderson, R. L. & Khosravi-Far, R. Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res. 66, 6304-6311 (2006).
50. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002).
51. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
52. Smyth, M. J., Crowe, N. Y. & Godfrey, D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463 (2001).
53. Zerafa, N. et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586-5590 (2005).
54. Yue, H. H., Diehl, G. E. & Winoto, A. Loss of TRAIL-R. does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 12, 94-97 (2005).
55. Grosse-Wilde, A. et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 118, 100-110 (2008).
56. Lee, S. H. et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59, 5683-5686 (1999).
57. Lee, S. H. et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20, 399-403 (2001).
58. Fisher, M. J. et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7, 1688-1697 (2001).
59. Shin, M. S. et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61, 4942-4946 (2001).
60. Bin, L. et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J. Biol. Chem. 282, 28189-28194 (2007).
61. MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. & Cohen, G. M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65, 11265-11270 (2005).
62. van der Sloot, A. M. et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl Acad. Sci. USA 103, 8634-8639 (2006).
63. Wolf, S. et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int. J. Cancer 118, 1831-1835 (2006).
64. Frank, B. et al. Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 15, 2002-2005 (2006).
65. Horak, P. et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin. Cancer Res. 11, 8585-8591 (2005).
66. Martinez-Ferrandis, J. I. et al. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomarkers 3, 89-93 (2007).
67. Sanlioglu, A. D. et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 69, 716-723 (2007).
68. MacPherson, G. et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl Cancer Inst. 96, 1866-1869 (2004).
69. Teitz, T. et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med. 6, 529-535 (2000).
70. Hopkins-Donaldson, S. et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 60, 4315-4319 (2000).
71. Harada, K. et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21, 4345-4349 (2002).
72. Fulda, S. et al. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res. 66, 10016-10023 (2006).
73. Yang, Q. et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin. Cancer Res. 13, 3191-3197 (2007).
74. Ullenhag, G. J. et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 13, 5070-5075 (2007).
75. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
76. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157-163 (1999). References 75 and 76 provided the first evidence that rTRAIL had anti-tumour activity in vivo and could be safely administered to experimental animals.
77. Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891-4898 (2001).
78. Griffith, T. S. et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189, 1343-1354 (1999).
79. Ichikawa, K. et al. Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954-960 (2001). Important description of an agonistic anti-DR5 mAb leading to clinical trials.
80. Motoki, K. et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11, 3126-3135 (2005).
81. Pukac, L. et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92, 1430-1441 (2005).
82. Zeng, Y. et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int. J. Oncol. 28, 421-430 (2006).
83. Kelley, R. F. et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280, 2205-2212 (2005).
84. MacFarlane, M. et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12, 773-782 (2005).
85. Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437-448 (2004).
86. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J. V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl Acad. Sci. USA 95, 652-656 (1998).
87. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000). Key paper demonstrating the importance of FcR in the anti-tumour activity of therapeutic antibodies.
88. Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141-143 (1997).
89. Wen, J. et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96, 3900-3906 (2000).
90. Meurette, O. et al. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann. N. Y. Acad. Sci. 1090, 209-216 (2006).
91. Koschny, R., Walczak, H. & Ganten, T. M. The promise of TRAIL - potential and risks of a novel anticancer therapy. J. Mol. Med. 85, 923-935 (2007).
92. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769-784 (2006).
93. Guo, F. et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64, 2580-2589 (2004).
94. Rosato, R. R., Almenara, J. A., Dai, Y. & Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273-1284 (2003).
95. Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 66, 1537-1545 (2003).
96. Lindemann, R. K. et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA 104, 8071-8076 (2007).
97. Vanoosten, R. L., Moore, J. M., Ludwig, A. T. & Griffith, T. S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 11, 542-552 (2005).
98. Volkmann, X. et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46, 1498-1508 (2007).
99. Frew, A. J. et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl Acad. Sci. USA 105, 11317-11322 (2008).
100. Martelli, A. M. et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17, 1794-1805 (2003).
101. Bremer, E. et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 280, 10025-10033 (2005).
102. Bortul, R. et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation. Leukemia 17, 379-389 (2003).
103. Thakkar, H. et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem. 276, 38361-38369 (2001).
104. Kim, K. M. & Lee, Y. J. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 24, 355-366 (2005).
105. Panner, A., James, C. D., Berger, M. S. & Pieper, R. O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25, 8809-8823 (2005).
106. McCubrey, J. A. et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22, 708-722 (2008).
107. Safa, A. R., Day, T. W. & Wu, C. H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets. 8, 37-46 (2008).
108. Bockbrader, K. M., Tan, M. & Sun, Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24, 7381-7388 (2005).
109. Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and TNF?-mediated cell death. Science 305, 1471-1474 (2004).
110. Karikari, C. A. et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6, 957-966 (2007).
111. Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693 (2007).
112. Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681 (2007).
113. Petersen, S. L. et al. Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445-456 (2007).
114. Gaither, A. et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res. 67, 11493-11498 (2007).
115. Aza-Blanc, P. et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12, 627-637 (2003).
116. Rottmann, S., Wang, Y., Nasoff, M., Deveraux, Q. L. & Quon, K. C. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc. Natl Acad. Sci. USA 102, 15195-15200 (2005).
117. Ovcharenko, D., Kelnar, K., Johnson, C., Leng, N. & Brown, D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 67, 10782-10788 (2007).
118. Wang, Y. et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5, 501-512 (2004). References 115-118 describe synthetic lethal screens to identify regulators of TRAIL-mediated apoptosis. Three of the screens used siRNA libraries.
119. Ricci, M. S. et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 24, 8541-8555 (2004).
120. Pardoll, D. & Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nature Med. 10, 887-892 (2004).
121. Uno, T. et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nature Med. 12, 693-698 (2006).
122. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
123. Smyth, M. J. et al. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J. Immunol. 176, 6347-6355 (2006).
124. Smyth, M. J. et al. IL-21 enhances antibody-mediated tumor rejection. Cancer Res. 68, 1-7 (2008).
125. Hallett, W. H. et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 180, 163-170 (2008).
126. Maddipatla, S., Hernandez-Ilizaliturri, F. J., Knight, J. & Czuczman, M. S. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin. Cancer Res. 13, 4556-4564 (2007).
127. Daniel, D. et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110, 4037-4046 (2007).
128. Daniels, R. A. et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 15, 430-438 (2005).
129. Degli-Esposti, M. To die or not to die - the quest of the TRAIL receptors. J. Leukoc. Biol. 65, 535-542 (1999).
130. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821 (1997).
131. Tolcher, A. W. et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25, 1390-1395 (2007).
132. Le, L. H. et al. Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. 22, 2533 (2004).
133. Hotte, S. J. et al. HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. J. Clin. Oncol. 23, 3052 (2004).
134. Chow, L. Q. et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study. J. Clin. Oncol.24, 2515 (2006).
135. Greco, F. A. et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer (2008).
136. Younes, A. et al. Results of a phase 2 trial of HGSETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 106, Abstract 489 (2005).
137. Plummer, R. et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13, 6187-6194 (2007). References 131 and 137 are the first published results of early-phase clinical trials using anti-TRAILR2 (lexatumumab) and -TRAILR1 (mapatumumab) mAbs respectively.
138. Patnaik, A. et al. HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. J. Clin. Oncol. 24, 3012 (2006).
139. Sikic, B. I. et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J. Clin. Oncol. 25, 14006 (2007).
140. Rowinsky, E. K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 23, 9394-9407 (2005).
141. LoRusso, P. et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J. Clin. Oncol. 25, 3534 (2007).
142. Camidge, D. et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J. Clin. Oncol. 25, 3582 (2007).
143. Herbst, R. S. et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. 24, 3013 (2006).
144. Ling, J. et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J. Clin. Oncol. 24, 3047 (2006).
145. Pan, Y. et al. Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. J. Clin. Oncol. 25, 3535 (2007).
146. Yee, L. et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J. Clin. Oncol. 25, 8078 (2007).
147. Jo, M. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med. 6, 564-567 (2000).
148. Lawrence, D. et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Med. 7, 383-385 (2001).
149. Mori, E. et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 11, 203-207 (2004).
150. Qin, J., Chaturvedi, V., Bonish, B. & Nickoloff, B. J. Avoiding premature apoptosis of normal epidermal cells. Nature Med. 7, 385-386 (2001). References 147-150 describe apoptosis of normal cells induced by TRAIL that is dependent on the method used for production of the recombinant soluble protein. Non-tagged, zinc-containing rTRAIL was not toxic against cultured primary hepatocytes or keratinocytes.
151. Kahraman, A. et al. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 47, 1317-1330 (2008).
152. Takeda, K. et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc. Natl Acad. Sci. USA 105, 10895-10900 (2008).
153. Hayakawa, Y. et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 172, 123-129 (2004).
154. Leverkus, M. et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood 96, 2628-2631 (2000).
155. Diehl, G. E. et al. TRAIL-R. as a negative regulator of innate immune cell responses. Immunity 21, 877-889 (2004).
156. Higuchi, H., Bronk, S. F., Taniai, M., Canbay, A. & Gores, G. J. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J. Pharmacol. Exp. Ther. 303, 461-467 (2002).
157. Janssen, H. L., Higuchi, H., Abdulkarim, A. & Gores, G. J. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J. Hepatol 39, 414-420 (2003).
158. Mundt, B. et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17, 94-96 (2003).
159. Mundt, B. et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54, 1590-1596 (2005).
160. Pan, G. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (1997).
161. Degli-Esposti, M. A. et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165-1170 (1997).
162. Marsters, S. A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003-1006 (1997).
163. Griffith, T. S. et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162, 2597-2605 (1999).
164. Clancy, L. et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl Acad. Sci. USA 102, 18099-18104 (2005).
165. Merino, D. et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 26, 7046-7055 (2006).
166. Chaudhary, P. M. et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7, 821-830 (1997).
167. Romagnoli, M. et al. Canonical nuclear factor κB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res. 13, 6010-6018 (2007).
168. Ravi, R. et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nature Cell Biol. 3, 409-416 (2001).
169. Roue, G. et al. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J. Immunol. 178, 1923-1930 (2007).
170. Khanbolooki, S. et al. Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5, 2251-2260 (2006).
171. Morales, J. C., Ruiz-Magana, M. J. & Ruiz-Ruiz, C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-κB inhibition. Mol. Immunol. 44, 2587-2597 (2007).
172. Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H. & Karin, M. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305 (2004).
173. Ganten, T. M. et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42, 588-597 (2005).
174. Ishimura, N., Isomoto, H., Bronk, S. F. & Gores, G. J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G129-G136 (2006).
175. Chen, X., Kandasamy, K. & Srivastava, R. K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 63, 1059-1066 (2003).
176. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007).
177. Secchiero, P. et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107, 2250-2256 (2003).
178. Zauli, G. et al. PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. J. Cell Physiol. 202, 900-911 (2005).
179. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (2005).
180. Song, J. J. & Lee, Y. J. Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal 20, 892-906 (2008).
181. Siegmund, D. et al. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell Signal 19, 1172-1184 (2007).
182. Sah, N. K. et al. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J. Biol. Chem. 278, 20593-20602 (2003).
183. Weldon, C. B. et al. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int. J. Oncol. 24, 1473-1480 (2004).
184. Frese, S. et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22, 5427-5435 (2003).
185. Ohtsuka, T. et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22, 2034-2044 (2003).
186. Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997).
187. Schneider, P. et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-?B. Immunity 7, 831-836 (1997).
188. Wajant, H. Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol. Interv. 3, 124-127 (2003).
189. Mitsiades, C. S. et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res. 12, 3705-3712 (2006).
190. Vucic, D. & Fairbrother, W. J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 13, 5995-6000 (2007).
191. Vaux, D. L. & Silke, J. IAPs, RINGs and ubiquitylation. Nature Rev. Mol. Cell Biol. 6, 287-297 (2005).
192. Zhang, H. G., Wang, J., Yang, X., Hsu, H. C. & Mountz, J. D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23, 2009-2015 (2004).
193. Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53 (2000).
194. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42 (2000).
195. Ng, C. P. & Bonavida, B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 1, 1051-1058 (2002).
196. Vogler, M., Durr, K., Jovanovic, M., Debatin, K. M. & Fulda, S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26, 248-257 (2007).
197. Shamimi-Noori, S. et al. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther. 15, 356-370 (2008).
198. Belyanskaya, L. L. et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol. Cancer 6, 66 (2007).
199. El-Zawahry, A., McKillop, J. & Voelkel-Johnson, C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5, 2 (2005).
200. Dumitru, C. A., Carpinteiro, A., Trarbach, T., Hengge, U. R. & Gulbins, E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12, 1533-1541 (2007).
201. Broaddus, V. C. et al. Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J. Biol. Chem. 280, 12486-12493 (2005).
202. Shankar, S., Singh, T. R. & Srivastava, R. K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61, 35-49 (2004).
203. Ray, S. & Almasan, A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63, 4713-4723 (2003).
204. Shankar, S., Chen, X. & Srivastava, R. K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165-186 (2005).
205. Wang, X. et al. 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-κB pathway. Cancer Res. 66, 1089-1095 (2006).
206. Kim, K. M., Song, J. J., An, J. Y., Kwon, Y. T. & Lee, Y. J. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J. Biol. Chem. 280, 41047-41056 (2005).
207. Bai, J. et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 65, 2344-2352 (2005).
208. Deeb, D. et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-κB through suppression of IκBα phosphorylation. Mol. Cancer Ther. 3, 803-812 (2004).
209. Chawla-Sarkar, M. et al. Suppression of NF-κB survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J. Biol. Chem. 278, 39461-39469 (2003).
210. Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795-804 (2001).
211. Ricci, M. S. et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12, 66-80 (2007).
212. Lagneaux, L. et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp. Hematol. 35, 1527-1537 (2007).
213. 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis 12, 2101-2114 (2007).
214. Shrader, M. et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67, 1430-1435 (2007).
215. Chen, X. et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20, 6073-6083 (2001).
216. Rosato, R. R., Dai, Y., Almenara, J. A., Maggio, S. C. & Grant, S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridolmediated XIAP downregulation. Leukemia 18, 1780-1788 (2004).